UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 31, 2016

 

 

COHERUS BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-36721   27-3615821

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification Number)

333 Twin Dolphin Drive, Suite 600

Redwood City, CA 94065

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (650) 649-3530

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 8.01. Other Events.

On May 31, 2016, in connection with the underwritten public offering by Coherus BioSciences, Inc. (the “Company”) of its common stock that closed on May 26, 2016 (the “Offering”), Barclays Capital Inc. (the “Underwriter”) provided notice of exercise of its over-allotment option to purchase 525,000 additional shares (the “Additional Shares”) from the Company at the public offering price of $18.00 per share before deducting the underwriting discount. The Company expects the net proceeds from the Offering, including the 3,500,000 shares of common stock purchased at the initial closing on May 26, 2016 and the purchase of the Additional Shares, to be approximately $69.1 million, after underwriting discounts and commissions and estimated offering expenses.

A copy of the legal opinion and consent of Latham & Watkins LLP relating to the Additional Shares issued and sold in the Offering is attached as Exhibit 5.1 hereto.

 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

See Exhibit Index attached hereto.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    COHERUS BIOSCIENCES, INC.
Date: June 3, 2016     By:   /s/ Jean-Frédéric Viret
    Name:   Jean-Frédéric Viret
    Title:   Chief Financial Officer

EXHIBIT INDEX

 

Exhibit

No.

  

Description

  5.1    Opinion of Latham & Watkins LLP.
23.1    Consent of Latham & Watkins LLP (included in Exhibit 5.1).
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Coherus BioSciences Charts.
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Coherus BioSciences Charts.